An ELISA for the in vitro determination of human NGAL in urine, serum, plasma, tissue extracts or culture media.
|Target||Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)|
|Sample Type||Human urine and plasma|
|Numbers of tests||96 wells - 40 test in duplicate|
|Sample vol needed||10 µl|
|Dilution guideline||1/500 (Urine from healthy subjects)|
|Assay range||10-1000 pg/mL|
|Limit of Detection||4 pg/mL|
|Assay time||<4 hours|
|Result type||Quantitative (pg/mL)|
|Application||For in vitro diagnostic use in the European Union and Canada. RUO - Research Use Only in all other markets.|
*Not available in the USA for in vitro diagnostic use.
*For in vitro diagnostic use in the European Union, Canada and Iran. For research use only in all other terrirories.
NGAL is a new early biomarker for diagnosing acute kidney injury (AKI)
Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
Measuring NGAL in urine or plasma gives you information on AKI status that you need for rapid decision making e.g. in the following settings -
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.
Method patented/patent pending in selected countries.
For further patent information please click here